Viral Vector Manufacturing
In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development.
What Can Viral Vectors Be Used For?
Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors can be used for the treatment of various diseases such as:
- muscular,
- metabolic,
- hematologic,
- ophthalmologic,
- and infectious diseases as well as different types of cancer.
An increasing number of clinical trials in the field of viral vector therapy and viral vector manufacturing, confirms the value of this new medicinal technology, and several viral vector-based drugs have also been globally approved.
Therefore, these vectors represent a promising strategy e.g., against emerging diseases such as Covid-19. This is emphasized by the fact that several vector-based vaccines against SARS-CoV2 are already on the market.
Types of Viral Vectors in Development:
- adenoviruses,
- adeno-associated viruses (AAV),
- herpes simplex viruses (HSV),
- alphaviruses,
- flaviviruses,
- measles viruses,
- rhabdoviruses,
- retroviruses,
- lentiviruses,
- Newcastle disease virus,
- poxviruses as well as picornaviruses.
The spectrum of viral vectors is very broad and is focusing on delivery vehicles developed for transient short-term and permanent long-term expression. Moreover, the types of vectors are represented by both RNA and DNA viruses with either single-stranded (ss) or double-stranded (ds) genomes.
Viral Vector Manufacturing for Preclinic Development and Clinical Trials
After developing a pre-clinical viral vector concept and confirmation that the product works in the animal model, viral vector manufacturing of clinical (GMP) material for extended toxicity studies and human clinical trials is required. The selection of a safe and efficient cell line for production is therefore mandatory.
The Fastest Option to Move into Clinical Trials: Nuvonis "ready to use" GMP Vero Cell Banks for Viral Vector Manufacturing
A broad range of viral vectors can be grown in Vero cells and thus allows the production at a large scale with high productivity when using microcarrier-based technologies. WHO has recommended the use of well-characterised cell substrates back in 1998 (WHO Technical Report Series 878; Expert Committee on Biological Standardization). Due to its stability and well-documented performance regarding the quality and quantity of virus/vector yield, Vero cells are widely accepted by Regulatory Authorities incl. FDA.
Nuvonis’ GMP Vero cell banks are the fastest route to move into GMP manufacturing of viral vectors, as they are state of the art (animal component free), fully tested and immediately available. This allows you to move into trouble-free GMP production at the fastest possible timescale by relying on an established substrate for viral vector manufacturing.